IRVINE, Calif., June 27, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products announced today that it has appointed...
Tailwinds' Take: This financing was led by ICONIQ Capital, which is a Mark Zuckerberg led investment fund. All other investors (except one small one out of Singapore) are HK based. It appears the Watsons' rollout must be going well....
Tailwinds' Take: Revenue exceeded Company and Wall Street forecasts. Singapore launch coming in Q1. Well positioned for a huge 2018. IRVINE, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way...
IRVINE, Calif., June 12, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products announced today that it has signed...
IRVINE, Calif., Dec. 08, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a science-based, fully integrated nutraceutical company devoted to extending human healthspan, announced today that in research published in the journal Nature, Dr. Johan Auwerx showed that Alzheimer’s disease...
I had the opportunity to stop by the offices of ChromaDex (CDXC) last week in LA. It was a beautiful day in LA and I was in a good mood. From the Company's side, in attendance were Robert Fried,...
IRVINE, Calif., June 05, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products announced today that Charles Brenner, PhD, the...
IRVINE, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a science-based, fully integrated nutraceutical company devoted to extending human healthspan, announced today the financial results for the quarter ended September 30, 2017. Frank Jaksch, Jr., CEO and co-founder of ChromaDex commented, “The science continues to...
One of our top picks, Chromadex shares have been under pressure over the last few months. The shares hit a high of around $7 in November, but worked their way lower, trading as low as $4.50 last week. This...
As an investor in ChromaDex (CDXC), and a user of their lead product Tru Niagen, I'm a firm believer in the health benefits of Nicotinamide Riboside (NR). NR in its consumer form is more commonly known as Niagen, which is...